Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV). (MIACoV)
COVID-19
About this trial
This is an interventional prevention trial for COVID-19 focused on measuring Booster dose, Moderna, Pfizer, fractional and standard doses, COVID-19 vaccination, mRNA vaccine
Eligibility Criteria
Inclusion Criteria:
- Have completed two doses of Pfizer-BioNTech or AstraZeneca vaccines with the recommended schedule 6 months prior to the date of enrolment
- Willing and able to give written informed consent
- Aged 18 years or above
- Willing to complete the follow-up requirements of the study
Exclusion Criteria:
- Received 3 doses of COVID-19 vaccine
- Received 2 doses of COVID-19 less than 6 months prior to the start of the trial
- Received a different Covid-19 vaccine not available in Australia
- Currently on immunosuppressive medication or anti-cancer chemotherapy
- HIV infection
- Congenital immune deficiency syndrome
- Has received immunoglobulin or other blood products in the 3 months prior to vaccination
- Study staff and their relatives
- Have a history of a severe allergic reaction to any COVID-19 vaccines or have a medical exception to receiving further COVID-19 vaccines
- Cannot read or understand English
Sites / Locations
- Royal Children's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Active Comparator
Experimental
Active Comparator
Experimental
Active Comparator
Experimental
Active Comparator
Experimental
AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Standard Pfizer-BioNTech booster group
AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Fractional Pfizer-BioNTech booster group
AstraZeneca (ChAdOx1-S, or Vaxzevria®) Standard Elasomeran booster group
AstraZeneca (ChAdOx1-S, or Vaxzevria®)-Fractional Elasomeran booster group
Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Standard Pfizer-BioNTech booster group
Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Fractional Pfizer-BioNTech booster group
Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Standard Elasomeran booster group
Pfizer-BioNTech (BNT162b2, or Comirnaty®)-Fractional Elasomeran booster group
Received two doses of AstraZeneca as primary COVID-19 vaccine
Received two doses of AstraZeneca as primary COVID-19 vaccine
Received two doses of AstraZeneca as primary COVID-19 vaccine
Received two doses of AstraZeneca as primary COVID-19 vaccine
Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine
Received two doses of Pfizer-BioNTech as primary COVID-19 vaccine